Biotechnology - Mergers & Acquisitions, Financial

Filter

Popular Filters

1 to 25 of 36 results

Genesis 2013: Astex Pharma’s journey from biotech start-up to $886m success story

Genesis 2013: Astex Pharma’s journey from biotech start-up to $886m success story

16-12-2013

A biotech company’s dream 14-year journey from small start-up to an $886 million takeover bid provided…

Asia-PacificAstex PharmaceuticalsBiotechnologyFinancialInterviewsMergers & AcquisitionsOtsukaUKUSA

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

22-11-2013

US biotech firm Amicus Therapeutics saw its shares fall 4.2% to $2.03 by mid-morning trading on Thursday,…

Amicus TherapeuticsBiotechnologyCallidus BiopharmaFinancialGlaxoSmithKlineLicensingManagementMergers & AcquisitionsmigalastatRare diseases

Aphios spins off Amylon to develop novel Alzheimer’s disease drug

21-11-2013

US clinical-stage biotech firm Aphios says it has spun-off a subsidiary, Amylon, to finance, develop…

AmylonAPH-1104AphiosBiotechnologyFinancialMergers & AcquisitionsNeurologicalResearch

Osiris to sell culture-expanded MSCs business including Prochymal

11-10-2013

USA-based Osiris Therapeutics has entered into an agreement with a wholly-owned subsidiary of Mesoblast…

BiotechnologyFinancialMergers & AcquisitionsMesoblastOsiris TherapeuticsProchymal

July a strong month for life sciences IPOs and M&A

05-08-2013

The life sciences initial public offering (IPO) market continued to heat up in July as six life sciences…

BiotechnologyCubist PharmaceuticalsFinancialMergers & AcquisitionsPerrigoPharmaceuticalRoche

Valneva to sell French CMO operations to India's Biological E

07-06-2013

Biotech firm Valneva (Euronext: VLA), the company recently created through the merger of France's Vivalis…

Biological E LtdBiotechnologyEB66FinancialMergers & AcquisitionsProductionValneva

Life Sciences IPOs have biggest month - May - in 13 years, reports Burrill

07-06-2013

A total of eight life sciences companies went public on US exchanges in May, the busiest month for initial…

BiotechnologyFinancialLicensingMergers & AcquisitionsPharmaceutical

Biotech industry has "implementation gap" around demonstrating the value of products under development

07-05-2013

Ernst & Young's annual biotech report shows strong performance by major players but a challenging environment…

BiotechnologyEuropeFinancialMergers & AcquisitionsNorth AmericaResearch

Two life sciences IPOs and strengthening markets offer encouragement to Biotech sector

04-04-2013

Two companies focused on infectious disease successfully completed initial public offerings (IPOs) in…

BiotechnologyFinancialLicensingMergers & Acquisitions

Elan to unlock benefits for shareholders from Tysabri deal

05-03-2013

The board of Ireland-based drugmaker Elan Corp (NYSE:ELN) has approved the decision to initiate a unique…

Biogen IdecBiotechnologyElanFinancialMergers & AcquisitionsPharmaceuticalRoyalty PharmaTysabri

Bone Therapeutics invests in state-of-the-art cell therapy manufacturing facility and SCTS

25-02-2013

Belgium-based biopharmaceutical company Bone Therapeutics, focused on innovative cell therapy products…

BiotechnologyBone TherapeuticsEuropeFinancialMergers & AcquisitionsPreobProductionSkeletal Cell Therapy Support

Briefs: Sanofi to up stake in Regeneron; Bayer files for riociguat approval

12-02-2013

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) saw its shares rise 4.8% to $173.84 in early trading…

BayerBiotechnologyEuropeFinancialMergers & AcquisitionsNorth AmericaPharmaceuticalRegeneronRegulationRespiratory and PulmonaryriociguatSanofi

Sun Pharma gives up fight to take full control of Taro; Angel Biotech in administration

11-02-2013

Israel-based Taro Pharmaceutical Industries (Pink Sheets: TAROF) and Indian drugmaker Sun Pharmaceutical…

Angel BiomedicalAngel BiotechnologyBiotechnologyFinancialMergers & AcquisitionsPharmaceuticalSun Pharmaceutical IndustriesTaro Pharmaceuticals

Elan sells its Tysabri rights to Biogen; posts 2012 financials

07-02-2013

Ireland-based drugmaker Elan Corp (NYSE: ELN) said yesterday that partner US biotech firm Biogen Idec…

Biogen IdecBiotechnologyElanFinancialMergers & AcquisitionsNeurologicalPharmaceuticalTysabri

Zoetis IPO caps strong month for life sciences financings, says Burrill & Co

04-02-2013

Life sciences financing activity got a strong start in the New Year as companies raised $10.3 billion…

AllerganBiotechnologyFinancialMAP PharmaceuticalsMergers & AcquisitionsPfizerPharmaceuticalZoetis

Pfizer's Zoetis spin-off could raise $12 billion; BGI-Shenzhen updates on Complete Genomics deal

20-01-2013

Pfizer (NYSE: PFE), the world's largest drugmaker by sales, which has previously said it is spinning…

BGI-ShenzhenBiotechnologyComplete GenomicsFinancialMergers & AcquisitionsPfizerPharmaceuticalZoetis

Big pharma will increasingly tap M&A to close $100 billion growth gap

07-01-2013

Big pharma companies are facing a widening "growth gap" that will increase pressure to drive growth through…

BiotechnologyFinancialMergers & AcquisitionsPharmaceutical

Geron signs tentative deal with BioTime on stem cell assets

18-11-2012

A year after announcing its decision to exit stem cell therapy, the USA's Geron Corp (Nasdaq: GERN) has…

BiotechnologyBioTimeFinancialGeron CorpMergers & Acquisitions

M&A briefs: GlaxoSmithKline/Response Genetics; Bayer/Teva unit

16-09-2012

USA-based Response Genetics (Nasdaq: RGDX) last week entered into a purchase agreement with UK pharma…

BayerBiotechnologyFinancialGlaxoSmithKlineMergers & AcquisitionsPharmaceuticalResponse GeneticsTeva Pharmaceutical Industries

Lundbeck takes 5% stake in Biotie; amends Selincro licensing deal

07-09-2012

Danish CNS drug specialist Lundbeck A/S (LUND: DC) said this morning that it has made an investment of…

BiotechnologyBiotie TherapiesFinancialLicensingLundbeckMergers & AcquisitionsNeurologicalPharmaceuticalSelincro

Pharmaceutical supply chain in Japan sees squeezed margins

19-07-2012

Pressures felt in Japan as a result of the country's aging population, drug price revisions and patent…

Asia-PacificBiotechnologyFinancialMarkets & MarketingMergers & AcquisitionsPharmaceuticalPricing

BB Biotech rejects privatization proposal by Vontobel Group

16-07-2012

Swiss biotechnology investment fund BB Biotech (SIX: BION) has confirmed that Vontobel Group has made…

BB BiotechBiotechnologyEuropeFinancialMergers & AcquisitionsVontobel

French biotechnology a sector in need of new growth solutions

23-05-2012

The biotechnology industry in France is a dynamic sector mainly made up of small structures, but companies…

BiotechnologyEuropeFinancialMergers & Acquisitions

1 to 25 of 36 results

Back to top